Clinical Trial Update: A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients [Phase 3]

View source ↗

Summary

Phase 3 study evaluating APL-1202 as a single-agent oral treatment versus intravesical epirubicin in naïve intermediate-risk non-muscle invasive bladder cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• APL-1202 (APL-1202)

Snippet

Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris | Conditions: Non-muscle Invasive Bladder Cancer | Phase 3 | Status: UNKNOWN